Document Detail


Clinical presentation of heparin-induced thrombocytopenia.
MedLine Citation:
PMID:  9855179     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse effect of heparin that is important because of its relatively high frequency and its strong association with paradoxic venous and arterial thrombosis. As confirmatory laboratory assays are not always immediately available, physicians usually must make initial diagnostic and treatment decisions based on the clinical presentation alone. Three characteristic features of HIT can be helpful in distinguishing it from other causes of thrombocytopenia: (1) timing of the onset of thrombocytopenia, namely, a platelet count decrease that begins between days 5 and 8 (inclusive) of beginning heparin treatment; (2) mild to moderate severity of the thrombocytopenia, with platelet counts only rarely less than 15 x 10(9)/L; and (3) the development of large-vessel venous or arterial thrombosis in association with thrombocytopenia, or any of a number of unusual characteristic sequelae of HIT (warfarin-associated venous limb gangrene, bilateral adrenal hemorrhagic infarction, heparin-induced skin lesions, or acute systemic reactions following intravenous heparin bolus). In contrast to other drug-induced immune thrombocytopenia syndromes, HIT rarely is associated with bleeding. HIT is relatively common, occurring in as many as 3% of patients who receive unfractionated (UF) heparin for 2 weeks. Between 30% and 75% of patients with HIT develop thrombosis; thus, about 1% of patients who receive a course of heparin develop HIT-associated thrombosis. The observation that HIT is less likely to occur with low-molecular-weight heparin (LMWH) suggests that HIT ultimately may be preventable.
Authors:
T E Warkentin
Related Documents :
3997629 - Angiostrongylosis in a greyhound.
11057859 - Pre-clinical pharmacological profile of the novel glycoconjugate org 36764 with both fa...
24172229 - Management of subclavian artery in-stent restenosis.
10856979 - Fibrinolysis and thrombosis.
11229279 - Heparin in haemorrhagic infarction in cerebral venous sinus thrombosis.
6614589 - Post embolectomy thrombosis treated with intra-arterial streptokinase.
434739 - Biopsy-negative cranial arteritis with complete oculomotor nerve palsy.
23515169 - Intramural haematoma should be referred to as thrombosed-type aortic dissection.
12917189 - The value of combining anterior segment fluorescein angiography with indocyanine green ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Seminars in hematology     Volume:  35     ISSN:  0037-1963     ISO Abbreviation:  Semin. Hematol.     Publication Date:  1998 Oct 
Date Detail:
Created Date:  1999-02-19     Completed Date:  1999-02-19     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0404514     Medline TA:  Semin Hematol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  9-16; discussion 35-6     Citation Subset:  IM    
Affiliation:
Department of Pathology, McMaster University, Hamilton, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Heparin / adverse effects*
Humans
Platelet Count
Thrombocytopenia / chemically induced*,  complications,  diagnosis*
Thrombosis / etiology
Time Factors
Chemical
Reg. No./Substance:
9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pathophysiology and laboratory testing of heparin-induced thrombocytopenia.
Next Document:  Limitations of conventional treatment options for heparin-induced thrombocytopenia.